Search

Your search keyword '"Viiala N"' showing total 2 results
Start Over Author "Viiala N" Publisher wiley-blackwell
2 results on '"Viiala N"'

1. POLATUZUMAB, BENDAMUSTINE & RITUXIMAB EFFICACY IN RELAPSED/REFRACTORY TRIAL‐INELIGIBLE LARGE B CELL LYMPHOMA PATIENTS: AN AUSTRALIAN LYMPHOMA REGISTRY (LARDR) STUDY.

Author

Shaw, B., Chung, E., Wellard, C., Yoo, E., Bennett, R., Birks, C., Johnston, A., Cheah, C., Hamad, N., Simpson, J., Barraclough, A., Ku, M., Viiala, N., Ratnasingam, S., Armytage, T., Cochrane, T., Chong, G., Lee, D., Manos, K., and Keane, C.

Subjects
B cell lymphoma, RITUXIMAB, LYMPHOMAS
Abstract

Reasons for cessation included progressive disease 52%; bridging to other therapy 10%; death 6%; toxicity 4%. 8 pts received up to 2 subsequent lines of therapy, with 2 receiving CAR-T therapy. B Introduction: b RRDLBCL outcomes remain poor despite autologous transplant and CAR-T therapies offering potential cure to a minority. POLATUZUMAB, BENDAMUSTINE & RITUXIMAB EFFICACY IN RELAPSED/REFRACTORY TRIAL-INELIGIBLE LARGE B CELL LYMPHOMA PATIENTS: AN AUSTRALIAN LYMPHOMA REGISTRY (LARDR) STUDY. [Extracted from the article]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results